Nghiên cứu & Báo cáo
24 thg 9, 2026•1 phút đọc
AbbVie reports positive Phase 3 results for Qulipta in menstrual migraine
AbbVie’s Qulipta (atogepant) reduced migraine days versus placebo in a Phase 3 menstrual migraine study, meeting the primary endpoint and supporting label expansion.
Nghiên cứu & Báo cáo
23 thg 8, 2026•1 phút đọc
PMDA Concludes MoU with London School of Hygiene & Tropical Medicine
The Pharmaceuticals and Medical Devices Agency (PMDA) has signed a Memorandum of Understanding with the London School of Hygiene & Tropical Medicine to promote joint work in pharmaceutical research and regulatory science.
Nghiên cứu & Báo cáo
23 thg 8, 2026•1 phút đọc
PMDA Updates One-Stop Service Platform by ENSEMBLExJ
The Pharmaceuticals and Medical Devices Agency (PMDA) has refreshed the One-Stop Service Platform page for ENSEMBLExJ, providing updated information for stakeholders.